Novartis’ investigational drug, Leqvio (inclisiran), has demonstrated positive results in a Phase III clinical trial. The drug, which is administered twice yearly, significantly lowered low-density lipoprotein cholesterol (LDL-C) levels in patients at low or moderate risk of atherosclerotic cardiovascular disease (ASCVD).   The V-MONO study, which evaluated Leqvio as a monotherapy, compared its efficacy to both placebo and ezetimibe, a commonly used cholesterol-lowering medication. Patients en...